

POLICY NAME	Atopic Dermatitis Immunomodulator Therapies	POLICY #	3142P
--------------------	---	-----------------	-------

Criteria

Coverage Criteria of Preferred Products with Single Step Edit (Dupixent, Adbry, Ebglyss)

- ☐ Diagnosis of moderate to severe atopic dermatitis
 - $\geq 10\%$ of body surface area (BSA)
 - SCORing Atopic Dermatitis (SCORAD) index value of at least 25
- ☐ Age ≥ 6 months (Dupixent) or ≥ 12 years (Adbry and Ebglyss)
- ☐ Prescribed by or in consultation with a dermatologist (skin doctor), allergist (allergy doctor), or immunologist (doctor specializing in the study of immune systems)
- ☐ Documentation of trial, failure, or contraindication to ONE of the following:
 - Topical corticosteroids--acceptable contraindications include treatment of sensitive areas, steroid induced atrophy, long-term uninterrupted use
 - Topical calcineurin inhibitor (tacrolimus ointment or pimecrolimus cream)—acceptable contraindications include severely impaired skin barrier, risk or presence of malignancy

Coverage Criteria of Preferred Products with Double Step Edit (Cibinqo, Rinvoq)

- ☐ Diagnosis of moderate to severe atopic dermatitis
 - $\geq 10\%$ of body surface area (BSA)
 - SCORing Atopic Dermatitis (SCORAD) index value of at least 25
- ☐ Age 12 years or older
- ☐ Prescribed by or in consultation with a dermatologist (skin doctor), allergist (allergy doctor), or immunologist (immune system doctor).
- ☐ Documentation of trial, failure, or contraindication to ONE of the following:
 - Topical corticosteroids--acceptable contraindications include treatment of sensitive areas, steroid induced atrophy, long-term uninterrupted use
 - Topical calcineurin inhibitor (tacrolimus ointment or pimecrolimus cream)—acceptable contraindications include severely impaired skin barrier, risk or presence of malignancy
- ☐ Documentation of minimum 3 month trial, failure, or contraindication to one or more systemic drug product (examples include, but are not limited to Dupixent, Adbry, etc)

Exclusion Criteria – Any of the following prevents coverage

- ☐ Biologics, JAK inhibitors, and immunosuppressants used in combination will not be covered